Clinical Evaluation of GI Safer Naproxen for the Treatment of Osteoarthritis
Clinical Evaluation of GI Safer Naproxen for the Treatment of Osteoarthritis
批准号:
7925188
负责人:
Upendra Marathi
金额:
$79.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2011-04-30
关键词:
AcuteAdultAdverse eventAgeAnti Inflammatory AnalgesicsAnti-Inflammatory AgentsAnti-inflammatoryApplications GrantsArthritisCapitalCardiovascular systemCessation of lifeChronicChronic DiseaseClinicalClinical ResearchClinical TrialsClinical assessmentsCoxibsDataDegenerative polyarthritisDevelopmentDiseaseDoseDrug Delivery SystemsDrug FormulationsDrug KineticsEndoscopyEnvironmentEvaluationEventFundingGelatinGrantHealth Care CostsHumanIncidenceInflammationInflammatoryInjuryInvestigational New Drug ApplicationInvestmentsLecithinLifeMucous MembraneNaproxenNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNon-Steroidal Anti-Inflammatory AgentsOralPTGS2 genePainPatientsPharmaceutical PreparationsPharmacologic SubstancePhasePhospholipidsRandomizedResearch DesignRiskRodentSafetySmall Business Innovation Research GrantStudy SubjectSurfaceTestingTherapeutic EquivalencyToxic effectUlcerUnited States Food and Drug Administrationarmbasecapsulecardiovascular disorder riskcardiovascular risk factorcelecoxibchronic paincomparative effectivenesscomparative efficacycyclooxygenase 2designeffectiveness researchgastrointestinalhealthy volunteerimprovedinhibitor/antagonistlipophilicitynon-drugprogramspublic health relevanceresearch clinical testingsafety studystandard of care
中文摘要
描述(由申请方提供):PLx Pharma Inc.正在开发非甾体抗炎药(NSAID)的制剂,其具有降低的引起胃肠(GI)粘膜损伤的风险。挑战:慢性疼痛患者需要药物治疗,以提供有效的疼痛缓解,而不会增加心血管疾病或胃肠道毒性的风险。骨关节炎(OA)和其他慢性疼痛和炎症疾病的现行标准治疗不仅需要考虑胃肠道(GI)风险,还需要考虑心血管(CV)风险,因为几乎所有非甾体类抗炎药(NSAID),尤其是选择性环氧合酶-2(考克斯- 2)抑制剂,均显示会增加严重CV事件的风险。萘普生已成为大多数轻度/中度慢性炎症适应症的首选NSAID,因为它似乎很少或没有增加心血管不良事件的风险。然而,尽管具有良好的CV安全性,但众所周知,萘普生会引起严重的,在某些情况下危及生命的GI毒性。方法:使用基于磷脂的药物递送系统,提高有效的心中性NSAID,萘普生的胃肠道安全性。该口服制剂称为Naproxen-PC(PL 3100),旨在通过与表面活性磷脂(即磷脂酰胆碱(PC))的非共价预结合增加萘普生的亲脂性,使用非COX机制改善萘普生的GI安全性。本RC 3资助申请的主要目的是通过对Naproxen-PC与标准处方剂量的萘普生相比的GI安全性进行临床内镜评估,继续开发Naproxen-PC。具体目标:完成一项II期随机、活性对照、平行设计、概念验证临床试验,评价55岁或55岁以上健康志愿者接受500 mg Naproxen-PC或萘普生BID给药14天后胃十二指肠粘膜损伤的发生率(通过内镜检查评估)。拟定的概念验证研究是首次评价Naproxen-PC在人体中的GI安全性,并将比较处方抗炎剂量下Naproxen-PC与萘普生的GI安全性。该产品目前在资金方面处于“死亡谷”;需要对该产品的GI保护能力进行临床评价以进行合作(以及随之而来的大量投资),但目前的资金环境限制了可用于资助拟议研究的资金。RC 3授权机制将允许PLx跨越这个死亡之谷。如果Naproxen-PC制剂显示具有改善的GI安全性,与萘普生相比具有等效的镇痛和抗炎功效,则它将代表数百万骨关节炎和相关慢性炎症疾病患者的重要新药。
公共卫生相关性:慢性疼痛患者需要药物治疗,以提供有效的疼痛缓解,而不会增加心血管疾病或胃肠道毒性的风险。萘普生已成为大多数轻度/中度慢性炎症适应症的首选NSAID,因为它似乎很少或没有增加心血管不良事件的风险。然而,尽管具有良好的CV安全性,但众所周知,萘普生会引起严重的,在某些情况下危及生命的GI毒性。正在开发一种名为Naproxen-PC(PL 3100)的口服制剂,以使用一种名为磷脂酰胆碱(PC)的天然磷脂,通过非药物机制改善萘普生的GI安全性。本RC 3资助申请的目的是对Naproxen-PC与标准处方剂量的萘普生相比的GI安全性进行临床评估。拟定的概念验证研究是首次评价Naproxen-PC在人体中的GI安全性,并将比较处方抗炎剂量下Naproxen-PC与萘普生的GI安全性。该产品目前在资金方面处于“死亡谷”;需要对该产品的GI保护能力进行临床评价以进行合作(以及随之而来的大量投资),但目前的资金环境限制了可用于资助拟议研究的资金。RC 3授权机制将允许PLx跨越这个死亡之谷。如果Naproxen-PC制剂显示具有改善的GI安全性,与萘普生相比具有等效的镇痛和抗炎功效,则它将代表数百万骨关节炎和相关慢性炎症疾病患者的重要新药。
英文摘要
DESCRIPTION (provided by applicant): PLx Pharma Inc. is developing formulations of non-steroidal anti-inflammatory agents (NSAIDs) that have a reduced risk of causing injury to the gastrointestinal (GI) mucosa. The Challenge: Patients in chronic pain require medication that provides effective pain relief without increasing the risk of cardiovascular disease or gastrointestinal toxicity. The current standard of care for osteoarthritis (OA) and other chronic disorders of pain and inflammation requires consideration of not only gastrointestinal (GI) risk, but also cardiovascular (CV) risk, as nearly all non-steroidal anti-inflammatory drugs (NSAIDs), especially the selective cyclooxygenase-2 (COX- 2) inhibitors, have been shown to increase the risk of serious CV events. Naproxen has become the NSAID of choice for most mild/moderate chronic inflammatory indications, as it appears to have little or no increased risk of cardiovascular adverse events. However, in spite of its favorable CV safety profile, naproxen is well known to induce serious, and in some cases life-threatening, GI toxicity. The Approach: Improve the GI safety of an efficacious, cardioneutral NSAID, naproxen, using a phospholipid-based drug delivery system. This oral drug product, called Naproxen-PC (PL 3100), is intended to improve the GI safety of naproxen using a non-COX mechanism, by increasing the lipophilicity of naproxen via non-covalent pre-association with a surface-active phospholipid, namely phosphatidylcholine (PC). The major objective of this RC3 grant application is to continue the development of Naproxen-PC by conducting a clinical endoscopic assessment of the GI safety of Naproxen-PC compared with naproxen at a standard prescription dose. Specific Aim: Complete a Phase II randomized, actively controlled, parallel-design, proof-of-concept clinical trial evaluating the incidence of gastro duodenal mucosal damage, as assessed by endoscopy, in healthy volunteers age 55 or older, following administration of 500 mg Naproxen-PC or naproxen BID for 14 days. The proposed proof-of-concept study is the first evaluation of the GI safety of Naproxen-PC in humans and will compare the GI safety of Naproxen-PC versus naproxen at prescription anti-inflammatory doses. This product currently resides in the "Valley of Death" with respect to funding; the clinical evaluation of the GI protective ability of this product is required for partnering (and the substantial investment that would accompany it), but the current funding environment has limited the capital available to fund the proposed study. The RC3 grant mechanism will allow PLx to span this Valley of Death. If the Naproxen-PC formulation is shown to possess improved GI safety with equivalent analgesic and anti-inflammatory efficacy compared with naproxen, it will represent an important new pharmaceutical for literally millions of patients with osteoarthritis and related chronic inflammatory diseases.
PUBLIC HEALTH RELEVANCE: Patients in chronic pain require medication that provides effective pain relief without increasing the risk of cardiovascular disease or gastrointestinal toxicity. Naproxen has become the NSAID of choice for most mild/moderate chronic inflammatory indications, as it appears to have little or no increased risk of cardiovascular adverse events. However, in spite of its favorable CV safety profile, naproxen is well known to induce serious, and in some cases life-threatening, GI toxicity. An oral drug product called Naproxen-PC (PL 3100) is being developed to improve the GI safety of naproxen using a non-pharmaceutical mechanism, using a naturally derived phospholipid called phosphatidylcholine (PC). The objective of this RC3 grant application is to conduct a clinical assessment of the GI safety of Naproxen-PC compared with naproxen at a standard prescription dose. The proposed proof-of-concept study is the first evaluation of the GI safety of Naproxen-PC in humans and will compare the GI safety of Naproxen-PC versus naproxen at prescription anti-inflammatory doses. This product currently resides in the "Valley of Death" with respect to funding; the clinical evaluation of the GI protective ability of this product is required for partnering (and the substantial investment that would accompany it), but the current funding environment has limited the capital available to fund the proposed study. The RC3 grant mechanism will allow PLx to span this Valley of Death. If the Naproxen-PC formulation is shown to possess improved GI safety with equivalent analgesic and anti-inflammatory efficacy compared with naproxen, it will represent an important new pharmaceutical for literally millions of patients with osteoarthritis and related chronic inflammatory diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A small molecule integrin activator to enhance cord blood transplant
-
批准号:9139272
-
项目类别:
-
资助金额:$29.59万
-
财政年份:2016
-
负责人:Upendra Marathi
-
依托单位:
A small molecule integrin activator to enhance cord blood transplant
-
批准号:9907800
-
项目类别:
-
资助金额:$93.6万
-
财政年份:2016
-
负责人:Upendra Marathi
-
依托单位:
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
-
批准号:9138564
-
项目类别:
-
资助金额:$31.37万
-
财政年份:2016
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
-
批准号:7910222
-
项目类别:
-
资助金额:$15.79万
-
财政年份:2010
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
-
批准号:8313502
-
项目类别:
-
资助金额:$56.54万
-
财政年份:2010
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
-
批准号:8434115
-
项目类别:
-
资助金额:$55.29万
-
财政年份:2010
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related
-
批准号:7657930
-
项目类别:
-
资助金额:$74.57万
-
财政年份:2009
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related
-
批准号:7537759
-
项目类别:
-
资助金额:$26.36万
-
财政年份:2008
-
负责人:Upendra Marathi
-
依托单位:
海外基金